HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Anna Linda Zignego Selected Research

N- (3- amino- 1- (cyclobutylmethyl)- 2,3- dioxopropyl)- 3- (2- ((((1,1- dimethylethyl)amino)carbonyl)amino)- 3,3- dimethyl- 1- oxobutyl)- 6,6- dimethyl- 3- azabicyclo(3.1.0)hexan- 2- carboxamide

9/2014Triple antiviral therapy in hepatitis C virus infection with or without mixed cryoglobulinaemia: a prospective, controlled pilot study.
1/2014Individualized treatment of genotype 1 naïve patients: an Italian multicenter field practice experience.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Anna Linda Zignego Research Topics

Disease

31Infections
06/2021 - 10/2002
26Cryoglobulinemia
01/2021 - 08/2003
18Vasculitis (Vasculitides)
10/2022 - 12/2007
12Liver Diseases (Liver Disease)
02/2019 - 09/2007
11Fibrosis (Cirrhosis)
01/2020 - 04/2006
8Chronic Hepatitis C
05/2021 - 09/2007
7Lymphoproliferative Disorders (Lymphoproliferative Disorder)
11/2020 - 11/2005
6Lymphoma (Lymphomas)
12/2022 - 09/2011
6Neoplasms (Cancer)
11/2020 - 11/2005
6Hepatitis C
10/2018 - 08/2013
4COVID-19
01/2022 - 01/2021
4Hepatitis
01/2022 - 01/2014
4Disease Progression
01/2021 - 06/2014
4Liver Cirrhosis (Hepatic Cirrhosis)
09/2018 - 09/2007
4Virus Diseases (Viral Diseases)
01/2018 - 09/2007
4Persistent Infection
11/2017 - 01/2011
3Non-Hodgkin Lymphoma (Lymphosarcoma)
10/2022 - 01/2013
3Hepatocellular Carcinoma (Hepatoma)
01/2021 - 07/2002
3Systemic Vasculitis
09/2018 - 06/2004
3Carcinogenesis
10/2015 - 01/2009
2Mental Disorders (Mental Disorder)
01/2022 - 01/2014
2Sjogren's Syndrome (Sjogren Syndrome)
01/2022 - 03/2017
2Rheumatic Diseases (Rheumatism)
06/2021 - 01/2017
2Rheumatoid Arthritis
01/2021 - 01/2020
2Inflammation (Inflammations)
01/2020 - 09/2007
2Anemia
11/2016 - 03/2016
2Hemophilia A (Haemophilia)
06/2014 - 03/2014
2Autoimmune Diseases (Autoimmune Disease)
01/2013 - 11/2005
1Clinical Deterioration
01/2022
1Interstitial Lung Diseases (Interstitial Lung Disease)
12/2021
1Hematologic Neoplasms (Hematological Malignancy)
12/2020
1Hypertension (High Blood Pressure)
10/2018
1Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse)
09/2018
1B-Cell Lymphoma (Lymphoma, B Cell)
09/2018
1Chronic Hepatitis B
07/2017

Drug/Important Bio-Agent (IBA)

30Antiviral Agents (Antivirals)IBA
12/2022 - 10/2002
14Rituximab (Mabthera)FDA Link
12/2021 - 09/2007
10CryoglobulinsIBA
01/2021 - 03/2015
9InterferonsIBA
10/2018 - 08/2003
8Biomarkers (Surrogate Marker)IBA
01/2021 - 01/2013
8Ribavirin (Virazole)FDA LinkGeneric
10/2018 - 08/2003
5Rheumatoid FactorIBA
01/2022 - 03/2017
5MicroRNAs (MicroRNA)IBA
11/2020 - 01/2012
5Antigen-Antibody Complex (Immune Complex)IBA
01/2017 - 06/2004
4Biological ProductsIBA
01/2021 - 09/2007
4Immunoglobulin G (IgG)IBA
01/2021 - 11/2017
4RNA (Ribonucleic Acid)IBA
08/2016 - 08/2003
3Antirheumatic Agents (DMARD)IBA
01/2022 - 01/2021
3Proteins (Proteins, Gene)FDA Link
01/2020 - 07/2002
3Pharmaceutical PreparationsIBA
01/2018 - 09/2014
3DNA (Deoxyribonucleic Acid)IBA
07/2016 - 06/2004
3CytokinesIBA
08/2013 - 12/2004
2B-Cell Activating FactorIBA
10/2022 - 01/2017
2SteroidsIBA
01/2022 - 01/2017
2Aspirin (Acetylsalicylic Acid)FDA LinkGeneric
01/2022 - 01/2021
2NucleotidesIBA
01/2021 - 07/2017
2NucleosidesIBA
01/2021 - 07/2017
2dasabuvirIBA
10/2018 - 01/2017
2Ritonavir (Norvir)FDA Link
10/2018 - 01/2017
2paritaprevirIBA
10/2018 - 01/2017
2ombitasvirIBA
10/2018 - 01/2017
2AutoantibodiesIBA
09/2018 - 03/2015
2Cyclophosphamide (Cytoxan)FDA LinkGeneric
01/2017 - 01/2017
2telaprevirIBA
03/2016 - 01/2014
2N- (3- amino- 1- (cyclobutylmethyl)- 2,3- dioxopropyl)- 3- (2- ((((1,1- dimethylethyl)amino)carbonyl)amino)- 3,3- dimethyl- 1- oxobutyl)- 6,6- dimethyl- 3- azabicyclo(3.1.0)hexan- 2- carboxamideIBA
09/2014 - 01/2014
2CXC ChemokinesIBA
08/2013 - 11/2012
2Interleukin-6 (Interleukin 6)IBA
08/2013 - 01/2011
2Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
08/2013 - 01/2011
2LigandsIBA
08/2013 - 11/2012
2Viral ProteinsIBA
01/2012 - 01/2009
2Monoclonal AntibodiesIBA
09/2011 - 09/2007
1B-Cell Activation Factor ReceptorIBA
10/2022
1VaccinesIBA
12/2021
1GlucocorticoidsIBA
12/2021
1Mycophenolic Acid (Cellcept)FDA LinkGeneric
12/2021
1Hepatitis B Surface Antigens (HBsAg)FDA Link
06/2021
1Immunosuppressive Agents (Immunosuppressants)IBA
06/2021
1glecaprevir and pibrentasvirIBA
05/2021
1Biosimilar PharmaceuticalsIBA
01/2021
1nasIBA
01/2021
1CT-P10IBA
01/2021
1Messenger RNA (mRNA)IBA
01/2021
1Genetic Markers (Genetic Marker)IBA
01/2021
1Notch ReceptorsIBA
12/2020
1Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
01/2020
1velpatasvirIBA
10/2018
1SofosbuvirIBA
10/2018
1AlbuminsIBA
10/2018
1Immunoglobulin M (IgM)IBA
09/2018

Therapy/Procedure

28Therapeutics
01/2022 - 10/2002
5Kidney Transplantation
02/2019 - 08/2012
4Renal Dialysis (Hemodialysis)
02/2019 - 10/2018
2Ambulatory Care (Outpatient Care)
01/2019 - 05/2018
2Liver Transplantation
01/2019 - 05/2018
2Drug Therapy (Chemotherapy)
09/2018 - 08/2012
2Retreatment
01/2017 - 09/2015
2Aftercare (After-Treatment)
09/2007 - 05/2006
1Precision Medicine
01/2021
1Immunotherapy
01/2018
1Treatment Delay
12/2017